Monopar Therapeutics Announces Significant Preclinical Data for MNPR-101 Radiopharma Program Targeting Advanced Cancers.

Monopar Therapeutics Inc., an innovative clinical-stage biopharmaceutical company, recently announced promising preclinical data for its MNPR-101 Radiopharma Program. The program is specifically designed to target advanced cancers, offering hope for millions of patients worldwide. $Monopar Therapeutics(MNPR.US)$